{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T01:35:07Z","timestamp":1768095307168,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"am","delay-in-days":310,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI044616"],"award-info":[{"award-number":["AI044616"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM049551"],"award-info":[{"award-number":["GM049551"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI141172"],"award-info":[{"award-number":["AI141172"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI112443"],"award-info":[{"award-number":["AI112443"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI122384"],"award-info":[{"award-number":["AI122384"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["EB000487"],"award-info":[{"award-number":["EB000487"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yale Macromolecular X-ray Core Facility","award":["1S10OD018007-01"],"award-info":[{"award-number":["1S10OD018007-01"]}]},{"DOI":"10.13039\/100000015","name":"DOE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006224","name":"Argonne National Laboratory","doi-asserted-by":"publisher","award":["DE-AC02-06CH11357"],"award-info":[{"award-number":["DE-AC02-06CH11357"]}],"id":[{"id":"10.13039\/100006224","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of General Medical Sciences from the National Institutes of Health","award":["P30 GM124165"],"award-info":[{"award-number":["P30 GM124165"]}]},{"name":"NIH-ORIP HEI","award":["S10OD021527"],"award-info":[{"award-number":["S10OD021527"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.antiviral.2019.04.010","type":"journal-article","created":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T02:14:51Z","timestamp":1556244891000},"page":"110-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV"],"prefix":"10.1016","volume":"167","author":[{"given":"Shalley N.","family":"Kudalkar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irfan","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna K.","family":"Mandl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Cisneros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagadish","family":"Beloor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert H.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Quijano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Mark","family":"Saltzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William L.","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priti","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.04.010_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.antiviral.2019.04.010_bib2","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1016\/j.bmcl.2013.06.091","article-title":"Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility","volume":"23","author":"Bollini","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2019.04.010_bib3","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1007\/s11051-014-2527-7","article-title":"Overview of nano-drugs characteristics for clinical application: the journey from the entry to the exit point","volume":"16","author":"Bose","year":"2014","journal-title":"J. Nanoparticle Res."},{"key":"10.1016\/j.antiviral.2019.04.010_bib4","first-page":"1","article-title":"[Review of a technic for the estimation of area under the concentration curve in pharmacokinetic analysis]","volume":"48","author":"Bourget","year":"1993","journal-title":"Therapie"},{"key":"10.1016\/j.antiviral.2019.04.010_bib5","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nrd3845","article-title":"Reducing safety-related drug attrition: the use of in vitro pharmacological profiling","volume":"11","author":"Bowes","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2019.04.010_bib6","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1107\/S0907444994003112","article-title":"The CCP4 suite: programs for protein crystallography","volume":"1","author":"Collaborative Computational Project","year":"1994","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"5","key":"10.1016\/j.antiviral.2019.04.010_bib7","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1073\/pnas.0711209105","article-title":"High-resolution structures of HIV-1 reverse transcriptase\/TMC278 complexes: strategic flexibility explains potency against resistance mutations","volume":"105","author":"Das","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2019.04.010_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063623","article-title":"Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction","volume":"8","author":"de Waal","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.04.010_bib9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/jmv.2055","article-title":"Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen","volume":"65","author":"Delaugerre","year":"2001","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2019.04.010_bib10","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.antiviral.2019.04.010_bib11","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.antiviral.2019.04.010_bib12","doi-asserted-by":"crossref","first-page":"19501","DOI":"10.1021\/ja3092642","article-title":"Crystal structures of HIV-1 reverse transcriptase with picomolar inhibitors reveal key interactions for drug design","volume":"134","author":"Frey","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2019.04.010_bib13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/cbdd.12266","article-title":"Structure-based evaluation of C5 derivatives in the catechol diether series targeting HIV-1 reverse transcriptase","volume":"83","author":"Frey","year":"2014","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.antiviral.2019.04.010_bib14","article-title":"Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy","author":"Gao","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.antiviral.2019.04.010_bib15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C subfamily","volume":"52","author":"Goldstein","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.antiviral.2019.04.010_bib16","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1021\/acsmedchemlett.5b00254","article-title":"Potent inhibitors active against HIV reverse transcriptase with K101P, a mutation conferring rilpivirine resistance","volume":"6","author":"Gray","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2019.04.010_bib17","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ejmech.2015.01.042","article-title":"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches","volume":"92","author":"Huang","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.04.010_bib18","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1021\/jm040840e","article-title":"In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)","volume":"48","author":"Janssen","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.04.010_bib19","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1021\/acs.molpharmaceut.5b00544","article-title":"Nanoparticle-based ARV drug combinations for synergistic inhibition of cell-free and cell-cell HIV transmission","volume":"12","author":"Jiang","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.antiviral.2019.04.010_bib20","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1021\/ar800236t","article-title":"Efficient drug lead discovery and optimization","volume":"42","author":"Jorgensen","year":"2009","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.antiviral.2019.04.010_bib21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0169-409X(02)00008-X","article-title":"Prediction of drug solubility from structure","volume":"54","author":"Jorgensen","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.antiviral.2019.04.010_bib22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","article-title":"Xds","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.antiviral.2019.04.010_bib51","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1128\/AAC.46.6.1640-1646.2002","article-title":"Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors","volume":"46","author":"King","year":"2002","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.antiviral.2019.04.010_bib23","series-title":"International Tables for Crystallography, Volume F","author":"Kleywegt","year":"2001"},{"key":"10.1016\/j.antiviral.2019.04.010_bib24","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1126\/science.1377403","article-title":"Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor","volume":"256","author":"Kohlstaedt","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2019.04.010_bib25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1124\/mol.116.107755","article-title":"Structural and preclinical studies of computationally designed non-nucleoside reverse transcriptase inhibitors for treating HIV infection","volume":"91","author":"Kudalkar","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2019.04.010_bib26","doi-asserted-by":"crossref","first-page":"E802","DOI":"10.1073\/pnas.1717932115","article-title":"From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection","volume":"115","author":"Kudalkar","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2019.04.010_bib27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1107\/S0021889892009944","article-title":"PROCHECK: a program to check the stereochemical quality of protein structures","volume":"26","author":"Laskowski","year":"1993","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.antiviral.2019.04.010_bib28","article-title":"Preparation of drug nanoparticles by emulsion evaporation method","volume":"187","author":"Le Thi Mai","year":"2009","journal-title":"J. Phys. Conf. Ser."},{"key":"10.1016\/j.antiviral.2019.04.010_bib29","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1021\/acsmedchemlett.6b00390","article-title":"Design, conformation, and crystallography of 2-naphthyl phenyl ethers as potent anti-HIV agents","volume":"7","author":"Lee","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2019.04.010_bib30","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1021\/ml5003713","article-title":"Picomolar inhibitors of HIV-1 reverse transcriptase: design and crystallography of naphthyl phenyl ethers","volume":"5","author":"Lee","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2019.04.010_bib31","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1016\/j.bmcl.2015.06.074","article-title":"Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase","volume":"25","author":"Lee","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2019.04.010_bib32","doi-asserted-by":"crossref","first-page":"16705","DOI":"10.1021\/ja408917n","article-title":"Picomolar inhibitors of HIV reverse transcriptase featuring bicyclic replacement of a cyanovinylphenyl group","volume":"135","author":"Lee","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2019.04.010_bib33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.06.005","article-title":"Long-acting parenteral combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: a humanized mouse model study","volume":"156","author":"Mandal","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.04.010_bib34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0022-2836(68)90205-2","article-title":"Solvent content of protein crystals","volume":"33","author":"Matthews","year":"1968","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2019.04.010_bib35","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.antiviral.2019.04.010_bib36","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1107\/S0907444909029436","article-title":"Electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation","volume":"65","author":"Moriarty","year":"2009","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.antiviral.2019.04.010_bib37","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.01456","article-title":"Collaboration gets the most out of software","volume":"2","author":"Morin","year":"2013","journal-title":"eLife"},{"key":"10.1016\/j.antiviral.2019.04.010_bib38","first-page":"887","article-title":"Variation in pharmacokinetics of omeprazole and its metabolites by gender and CYP2C19 genotype in Pakistani male and female subjects","volume":"29","author":"Nazir","year":"2016","journal-title":"Pak. J. Pharm. Sci."},{"key":"10.1016\/j.antiviral.2019.04.010_bib39","series-title":"Holland-frei Cancer Medicine","article-title":"Principles of pharmacokinetics","author":"Ratain","year":"2003"},{"key":"10.1016\/j.antiviral.2019.04.010_bib40","article-title":"Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis","volume":"12","author":"Rhee","year":"2015","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2019.04.010_bib41","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"Riddler","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.04.010_bib42","author":"Smart"},{"key":"10.1016\/j.antiviral.2019.04.010_bib43","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.bmcl.2012.02.055","article-title":"Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"22","author":"Sun","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2019.04.010_bib44","unstructured":"The PyMOL Molecular Graphics System, V. x. S., LLC.."},{"key":"10.1016\/j.antiviral.2019.04.010_bib45","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jama.2016.8662","article-title":"Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack","volume":"316","author":"Wang","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2019.04.010_bib46","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10544-007-9139-2","article-title":"Zeta potential: a surface electrical characteristic to probe the interaction of nanoparticles with normal and cancer human breast epithelial cells","volume":"10","author":"Zhang","year":"2008","journal-title":"Biomed. Microdevices"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219301834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219301834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:28:54Z","timestamp":1759062534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354219301834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":47,"alternative-id":["S0166354219301834"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.04.010","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}